BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways

Immune checkpoint inhibitors (ICIs) such as the anti-PD-1 antibody Nivolumab, achieve remarkable clinical efficacy in patients with late stage cancers. However, only a small subset of patients benefit from this therapy. Numerous clinical trials are underway testing whether combining ICIs with other...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncoimmunology
Main Authors: Yue, Peng, Harper, Taylor, Bacot, Silvia M., Chowdhury, Monica, Lee, Shiowjen, Akue, Adovi, Kukuruga, Mark A., Wang, Tao, Feldman, Gerald M.
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2018
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6287803/
https://ncbi.nlm.nih.gov/pubmed/30546949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1512456
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki